EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 20 / No 12 (Décembre 2004) Med Sci (Paris), 20 12 (2004) 1100-1103 References
Free Access
Issue
Med Sci (Paris)
Volume 20, Number 12, Décembre 2004
Page(s) 1100 - 1103
Section M/S revues
DOI https://doi.org/10.1051/medsci/200420121100
Published online 15 December 2004
  1. Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease. What do we know ? What do we need to learn ? Where do we go from here ? National kidney foundation task force on cardiovascular disease. Am J Kidney Dis 1998; 32 : 853–906. [Google Scholar]
  2. Parfrey P, Foley R. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999; 10 : 1606–15. [Google Scholar]
  3. Uhlig K, Levey A, Sarnak M. Traditional cardiac risk factors in individuals with chronic kidney disease. Semin Dial 2003; 16 : 118–27. [Google Scholar]
  4. Longenecker J, Coresh J, Powe N, et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population : the CHOICE study. J Am Soc Nephrol 2002; 13 : 1918–27. [Google Scholar]
  5. US department of health and human services. National center for health statistics, third national health and nutrition examination survey, 1988–1994. NHANES III. Hyattsville, MD : Centers for Disease Control and Prevention, 1994. [Google Scholar]
  6. Oparil S, Oberman A. Nontraditional cardiovascular risk factors. Am J Med Sci 1999; 317 : 193–207. [Google Scholar]
  7. Madore F. Uremia-related metabolic cardiac risk factors in chronic kidney disease. Semin Dial 2003; 16 : 148–56. [Google Scholar]
  8. Foley R, Parfrey P, Harnett J, et al. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996; 28 : 53–61. [Google Scholar]
  9. Ganesh SK, Stack AG, Levin NW, et al. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12 : 2131–8. [Google Scholar]
  10. Ross R. Atherosclerosis : an inflammatory disease. N Engl J Med 1999; 340 : 115–26. [Google Scholar]
  11. Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98 :731–3. [Google Scholar]
  12. Ridker PM, Henekens CH, Furing JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342 : 836–43. [Google Scholar]
  13. Anonymous. C-reactive protein and atherosclerosis in dialysis patients. Nephrol Dial Transpl 1998; 13 : 2710–1. [Google Scholar]
  14. Zimmermann J, Herrlinger S, Pruy A, et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55 : 648–58. [Google Scholar]
  15. Ridker P, Cushman M, Stampfer M, et al. Inflammation, aspirin, and risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336 : 973–9. [Google Scholar]
  16. Ridker P, Rifai N, Pfeffer M, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The cholesterol and recurrent events (CARE) investigators. Circulation 1999; 100 : 230–5. [Google Scholar]
  17. Sies H. Oxidative stress : oxidants and antioxidants. Exp Physiol 1997; 82 :291–5. [Google Scholar]
  18. Kita T, Kume N, Minami M, et al. Role of oxidized LDL in atherosclerosis. Ann NY Acad Sci 2001; 947 : 199–205. [Google Scholar]
  19. Hasselwander O, Young IS. Oxidative stress in chronic renal failure. Free Radic Res 1998; 29 : 1–11. [Google Scholar]
  20. Boaz M, Matas Z, Biro A, et al. Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis. Kidney Int 1999; 56 : 1078–83. [Google Scholar]
  21. Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE) : randomised placebo-controlled trial. Lancet 2000; 356 : 1213–8. [Google Scholar]
  22. Moustapha A, Naso A, Nahlawi M, et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 1998; 97 : 138–41. [Google Scholar]
  23. Bostom AG, Shemin D, Verhoef P, et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study. Arterioscler Thromb Vasc Biol 1997; 17 : 2554–8. [Google Scholar]
  24. Mallamaci F, Zoccali C, Tripepi G, et al. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 2002; 61 : 609–14. [Google Scholar]
  25. Jungers P, Massy ZA, Khoa TN, et al. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients : a prospective study. Nephrol Dial Transpl 1997; 12 : 2597–602. [Google Scholar]
  26. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000; 102 : 1082–5. [Google Scholar]
  27. Ernst E, Resch K. Fribrinogen as a cardiovascular risk factor : a meta-analysis and review of the literature. Ann Intern Med 1993; 118 : 956–63. [Google Scholar]
  28. Han D, Haudenshild C, Hong M, et al. Evidence for a possible role of apoptosis in atherogenesis. Am J Pathol 1995; 147 : 267–77. [Google Scholar]
  29. Troyanov S, Hebert MJ, Masse M, et al. Soluble Fas : a novel predictor of atherosclerosis in dialysis patients. Am J Kidney Dis 2003; 41 : 1043–51. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.